Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.
Provider: Stock Traders Daily
Provider: New Constructs, LLC

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Boston Scientific Corp's Vercise DBS System Demonstrates Improvement In Motor Function For Patients With Parkinson's Disease

Tuesday, 18 Jun 2013 12:00am EDT 

Boston Scientific Corp announced that Patients with Parkinson's disease using the Boston Scientific Corporation's Vercise DBS (deep brain stimulation) System showed a significant improvement in motor scores according to interim data from the VANTAGE DBS study. Data from the six month follow-up of up to 40 participants enrolled in the VANTAGE trial were presented. Preliminary analysis of the VANTAGE study displays approximately 60% mean improvement in motor function at six months post implant, as assessed by UPDRS III1 when compared to baseline. The Boston Scientific sponsoredstudy was designed to document patient outcomes. These include effectiveness, safety, and health economic data derived from bilateral stimulation of the subthalamic nucleus (STN) in the brain using the implantable Vercise DBS System for the treatment of levodopa-responsive, moderate to severe idiopathic Parkinson's disease. Forty participants with Parkinson's disease were implanted bilaterally at six European centers. 

Company Quote

-0.28 -2.13%
25 Nov 2014